-week screening period to confirm severity and stability of voiding symptoms based on the IPSS. Patients were then randomly allocated in a double-blind fashion to one of two cetrorelix dose groups or placebo, in a 2:1:1 ratio. Patients were administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 (for treatment Arm A, those in Arm B received IM injection at week 0, 2 and placebo injections both at Week 26 and 28). Patients in treatment Arm C received placebo injections at Week 0, 2, 26 and 28. All patients were followed up to Week 52. The study included 420 patients overall, 212, 106, and 102 patients allocated to Arm A, B, and C, respectively.
The Company will host a conference call and webcast to discuss these results later today, Monday, December 7, 2009 at 4:30 p.m., Eastern Time.
Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Investors" section, or by telephone using the following numbers: (outside Canada): 888-231-8191, (Canada): 514-807-9895 or 647-427-7450. A replay of the webcast will also be available on the Company's website for a period of 30 days.
About the Phase 3 Program with Cetrorelix in BPH
The Phase 3 trial program involving more than 1,600 patients with symptomatic BPH in Canada, the United States and Europe has been completed. In addition to the efficacy trial Z-036, the program included a placebo-controlled safety and efficacy trial Z-033, the single-armed safety study Z-041, and the Thorough QT study Z-043. Results for all of these trials were disclosed recently.
Cetrorelix pamoate is a compound that was being investigated for the treatment of BPH. Cetrorelix is part of AEterna Zentaris' luteinizing hormone-releasing hormone (LHRH) antagonist therapeutic approach.
About AEterna Zentaris Inc.
Page: 1 2 3 Related biology technology :1
. AEterna Zentaris completes management team with the appointment of Chief Medical Officer2
. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York3
. AEterna Zentaris Announces Outcome of Managements Strategic Review4
. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment5
. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers6
. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California7
. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 20088
. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs9
. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights10
. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results11
. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia